Kim Richard, Saif Muhammad Wasif
Cleveland Clinic, Cleveland, OH, USA.
JOP. 2007 May 9;8(3):279-88.
Treatment of locally advanced pancreatic cancer is challenging. Despite continuing research, effective treatments continue to be elusive with median survival of only 8-12 months. Treatment options for locally advanced pancreatic cancer include radiation therapy, concurrent chemoradiation or chemotherapy. It is felt that radiation therapy is a suboptimal treatment as most of patients will die of systemic disease. In the past, radiation with 5-FU was the standard treatment for locally advanced pancreatic cancer. But now radiation has been used with combination other chemo agents such as paclitaxel or gemcitabine in order to increase the efficacy. Chemotherapy such as gemcitabine alone or gemcitabine doublet also has been studied in patients with locally advanced pancreatic cancer as well with overall survival being approximately the same magnitude as chemoradiation. The exact role of chemoradiation or chemotherapy in treatment of locally advanced pancreatic cancer is yet to be defined. Hence, this review summarizes and compares of role of radiation, chemoradiation and chemotherapy in treating this disease.
局部晚期胰腺癌的治疗具有挑战性。尽管研究不断，但有效的治疗方法仍然难以捉摸，中位生存期仅为8至12个月。局部晚期胰腺癌的治疗选择包括放射治疗、同步放化疗或化疗。人们认为放射治疗并非最佳治疗方法，因为大多数患者会死于全身性疾病。过去，5-氟尿嘧啶放疗是局部晚期胰腺癌的标准治疗方法。但现在，放疗已与其他化疗药物如紫杉醇或吉西他滨联合使用，以提高疗效。单独使用吉西他滨或吉西他滨双联化疗等化疗方法也在局部晚期胰腺癌患者中进行了研究，总体生存期与放化疗大致相同。放化疗或化疗在局部晚期胰腺癌治疗中的确切作用尚未明确。因此，本综述总结并比较了放疗、放化疗和化疗在治疗该疾病中的作用。
